Gao Jian, Hu Zhenhua, Liu Juanjuan, Liu Dawo, Wang Yanyan, Cai Mingbo, Zhang Danye, Tan Mingzi, Lin Bei
Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, 110004, China.
Med Oncol. 2014 May;31(5):920. doi: 10.1007/s12032-014-0920-9. Epub 2014 Apr 2.
The purpose of this study was to investigate the relationship between the expression of CD147 and Lewis y antigen in epithelial ovarian carcinoma tissues and resistance to chemotherapeutic drugs, and its underlying clinical significance, and to analyze the correlation between the expression of CD147 and Lewis y antigen. Ninety-two ovarian cancer patients were divided into a chemotherapeutic-drug-resistant group (34 patients) and a drug-sensitive group (58 patients). Immunohistochemical assays were used to measure CD147, and Lewis y antigen to investigate their correlation with chemotherapy resistance. Multivariate logistic regression was used to analyze the relationships between risk factors and resistance to chemotherapy in ovarian cancer. Cox's model was used to analyze the relationships between risk factors and prognosis. The proportion of tissues expressing CD147 and Lewis y antigen in the drug-resistant group were 94.12 and 91.67%, respectively, which were significantly higher than those in the sensitive group (77.59 and 60.34%, respectively). The multivariate analysis indicated that the expression of CD147 and Lewis y antigen and the pathological stage of the ovarian cancer were all independent risk factors for drug resistance. Expression of CD147 and Lewis y antigen was high in the resistant group, and they correlated positively with each other. The expression of CD147 and Lewis y antigen was significantly higher in the drug-resistant group and their expression correlated positively in the ovarian epithelium. The expression of CD147 and Lewis y antigen and the pathological stage of ovarian cancer were all independent risk factors for drug resistance and prognosis in ovarian cancer.
本研究旨在探讨上皮性卵巢癌组织中CD147与Lewis y抗原的表达与化疗耐药性之间的关系及其潜在的临床意义,并分析CD147与Lewis y抗原表达之间的相关性。92例卵巢癌患者被分为化疗耐药组(34例)和药物敏感组(58例)。采用免疫组织化学方法检测CD147和Lewis y抗原,以研究它们与化疗耐药性的相关性。采用多因素logistic回归分析卵巢癌危险因素与化疗耐药性之间的关系。采用Cox模型分析危险因素与预后之间的关系。耐药组中表达CD147和Lewis y抗原的组织比例分别为94.12%和91.67%,显著高于敏感组(分别为77.59%和60.34%)。多因素分析表明,CD147和Lewis y抗原的表达以及卵巢癌的病理分期均为耐药的独立危险因素。耐药组中CD147和Lewis y抗原的表达较高,且二者呈正相关。在卵巢上皮中,耐药组CD147和Lewis y抗原的表达显著更高,且二者表达呈正相关。CD147和Lewis y抗原的表达以及卵巢癌的病理分期均为卵巢癌耐药和预后的独立危险因素。